| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-111SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF5779-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-37736-0.025ml | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier-Free | NBP2-35199-1mg | |||
| Carrier-Free | NBP2-35199-100ug | |||
| Carrier-Free | NBP2-35199-500ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP3-08233 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier-Free | NBP2-35200-1mg | |||
| Carrier-Free | NBP2-35200-100ug | |||
| Carrier-Free | NBP2-35200-500ug | |||
![Knockdown Validated: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0012.jpg "<b>Genetic Strategies Validation. </b>Knockdown Validated: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo and synergizes with ionizing radiation to inhibit tumor growth( Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). Sections of PSN1 xenografts and in-vitro PSN1 cells fixed and stained with anti-NPM (red) and anti-p14ARF (green). Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested in HeLa cells with Dylight 488 (green). Nuclei were counterstained with DAPI (blue). Tubulin was stained with alpha tubulin (red).](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0006.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - ARF expression levels in OCI/AML3 cells after proteasome treatment. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0009.jpg)
![Flow Cytometry: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested at 1:400 in HeLa cells using an Alexa Fluor 488 secondary (shown in purple). M1 is defined by unstained cells.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Flow-Cytometry-NB200-111-img0007.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Analysis of HeLa Whole Cell Lysate (NB800-PC1) using p14ARF antibody (lot C) employing ECL detection method.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0008.jpg)
![Immunohistochemistry-Frozen: p14ARF/CDKN2A Antibody [NB200-111] - Mouse brain section, hippocampal (10 um thickness). 3% PFA perfused. 1:1000 dilultion. Image from verified customer review. Image using the Biotin form of this antibody.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunohistochemistry-Frozen-NB200-111-img0010.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203719.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212372.jpg)
![Immunocytochemistry/ Immunofluorescence: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo & synergizes with ionizing radiation to inhibit tumor growth(A) PSN1 xenografts (PSN1 cells co-injected with LTC-14 stellate cells) established in the flank of athymic nude mice were treated with MK-2206 (60 mg/kg-320 mg/kg) as indicated or beta -cyclo-dextrin (1.5 mg/ml) carrier. Xenograft tumors were lysed & lysates probed by western blot with the indicated antibodies. (B-D) Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). (B) Sections of PSN1 xenografts & in-vitro PSN1 cells fixed & stained with anti-NPM (red) & anti-p14ARF (green). (C) PSN1 xenografts treated with MK-2206 or carrier were stained with DAPI, anti-p53 (DO1) or p53mut (OP29 clone) (D) PSN1 xenografts treated with MK-2206 (60 mg/kg) or carrier were stained by immunohistochemical methods with anti-pS473-AKT, anti-phospho-S48-NPM (pS48-NPM) or p53. (E) PSN1 xenografts established in the flank of athymic nude mice were injected subcutaneously with two alternate day doses of MK-2206 (60 mg/kg) or carrier. Mice were subsequently treated with a single dose of IR (6 Gy) & tumor volumes measured regularly with callipers. Dash lines indicate tumor growth differential at 250 mm3. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203724.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205197.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212370.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205120.jpg)
![Western Blot: p16INK4a/CDKN2A Antibody (OTI4C11) [NBP2-45602] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY CDKN2A.](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-OTI4C11-Western-Blot-NBP2-45602-img0008.jpg "Western Blot: p16INK4a/CDKN2A Antibody (OTI4C11) [NBP2-45602] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY CDKN2A.")
![Immunocytochemistry/Immunofluorescence: p16INK4a/CDKN2A Antibody (OTI4C11) [NBP2-45602] - Analysis of HepG2 cells.](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-OTI4C11-Immunofluorescence-NBP2-45602-img0003.jpg)
![Immunohistochemistry: p16INK4a/CDKN2A Antibody (OTI4C11) [NBP2-45602] - Analysis of Carcinoma of Human liver tissue.](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-OTI4C11-Immunohistochemistry-NBP2-45602-img0007.jpg)
![Western Blot: p16INK4a/CDKN2A Antibody (OTI4C11) [NBP2-45602] - Analysis of extracts (35ug) from 9 different cell lines (HepG2: Human; HeLa: Human; HT29: Human; A549: Human; COS7: monkey; Jurkat: human; MDCK: Canine; PC12: Rat; MCF7: human)](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-OTI4C11-Western-Blot-NBP2-45602-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: p16INK4a/CDKN2A Antibody (OTI4C11) [NBP2-45602] - Analysis of COS7 cells transiently transfected by pCMV6-ENTRY CDKN2A.](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-OTI4C11-Immunofluorescence-NBP2-45602-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: p16INK4a/CDKN2A Antibody (OTI4C11) [NBP2-45602] - Analysis of HeLa cells.](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-OTI4C11-Immunofluorescence-NBP2-45602-img0002.jpg)
![Immunohistochemistry: p16INK4a/CDKN2A Antibody (OTI4C11) [NBP2-45602] - Analysis of Carcinoma of Human thyroid tissue.](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-OTI4C11-Immunohistochemistry-NBP2-45602-img0004.jpg)
![Immunohistochemistry: p16INK4a/CDKN2A Antibody (OTI4C11) [NBP2-45602] - Analysis of Adenocarcinoma of Human endometrium tissue.](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-OTI4C11-Immunohistochemistry-NBP2-45602-img0005.jpg)
![Immunohistochemistry: p16INK4a/CDKN2A Antibody (OTI4C11) [NBP2-45602] - Analysis of Human liver tissue.](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-OTI4C11-Immunohistochemistry-NBP2-45602-img0006.jpg)
![SDS-Page: Human p16 Protein [NBP2-35199]](http://images.novusbio.com/fullsize/Human-p16-Protein-SDS-Page-NBP2-35199-img0001.jpg "SDS-Page: Human p16 Protein [NBP2-35199]")
![Immunocytochemistry/ Immunofluorescence: p16INK4a/CDKN2A Antibody - BSA Free [NBP3-06986] - Validation of p16INK4a/CDKN2A In HeLa Cells. Immunofluorescent analysis of methanol-fixed HeLa cells labeling p16INK4a/CDKN2A with at 20 ug/mL, followed by goat anti-rabbit IgG secondary antibody at 1/1000 dilution (red) and Hoechst staining (blue). Alpha tubulin was stained with anti-alpha tubulin antibody following by goat anti-mouse IgG secondary antibody (green). Images were captured with confocal microscopy.](http://images.novusbio.com/fullsize/nbp3-06986_rabbit-p16ink4a-cdkn2a-pab-bsa-free-271120242074659.jpg "Immunocytochemistry/ Immunofluorescence: p16INK4a/CDKN2A Antibody - BSA Free [NBP3-06986] - Validation of p16INK4a/CDKN2A In HeLa Cells. Immunofluorescent analysis of methanol-fixed HeLa cells labeling p16INK4a/CDKN2A with at 20 ug/mL, followed by goat anti-rabbit IgG secondary antibody at 1/1000 dilution (red) and Hoechst staining (blue). Alpha tubulin was stained with anti-alpha tubulin antibody following by goat anti-mouse IgG secondary antibody (green). Images were captured with confocal microscopy.")
![<b>Genetic Strategies Validation. </b>Western Blot: p16INK4a/CDKN2A Antibody [NBP3-06986] - Loading: 10 ug of 293 WT cell lysates or CDKN2A KO cell lysates. Antibodies: CDKN2A, NBP3-06986 (2 ug/mL) and beta-actin (1 ug/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-Western-Blot-NBP3-06986-img0001.jpg)
![Western Blot: p16INK4a/CDKN2A Antibody [NBP3-06986] - Loading: 15 ug of lysates per lane. Antibodies: NBP3-06986 (2 ug/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-Western-Blot-NBP3-06986-img0003.jpg)
![Western Blot: p16INK4a/CDKN2A Antibody [NBP3-06986] - Loading: 15 ug of lysates per lane. Antibodies: CDKN2A (2 ug/mL), NBP3-06986 (2 ug/mL) and beta-actin (1 ug/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-Western-Blot-NBP3-06986-img0002.jpg)
![Immunohistochemistry: p16INK4a/CDKN2A Antibody - BSA Free [NBP3-06986] - Validation of p16INK4a/CDKN2A in Human Colon Tissue. Immunohistochemical analysis of paraffin-embedded human colon tissue using anti-p16INK4a/CDKN2A antibody at 5 ug/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.](http://images.novusbio.com/fullsize/nbp3-06986_rabbit-p16ink4a-cdkn2a-pab-bsa-free-2711202420115536.gif)
![Western Blot: p16INK4a/CDKN2A Antibody (0D0C8) [NBP3-15420] - Analysis of extracts of HeLa cells, using p16INK4a/CDKN2A Rabbit mAb (NBP3-15420) at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit. Exposure time: 3min.](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-0D0C8-Western-Blot-NBP3-15420-img0004.jpg "Western Blot: p16INK4a/CDKN2A Antibody (0D0C8) [NBP3-15420] - Analysis of extracts of HeLa cells, using p16INK4a/CDKN2A Rabbit mAb (NBP3-15420) at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit. Exposure time: 3min.")
![Immunocytochemistry/Immunofluorescence: p16INK4a/CDKN2A Antibody (0D0C8) [NBP3-15420] - Immunofluorescence analysis of HeLa cells using p16INK4a/CDKN2A Rabbit mAb (NBP3-15420) at dilution of 1:100 (40x lens). Blue: DAPI for nuclear staining.](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-0D0C8-Immunocytochemistry-Immunofluorescence-NBP3-15420-img0003.jpg)
![Immunohistochemistry-Paraffin: p16INK4a/CDKN2A Antibody (0D0C8) [NBP3-15420] - Human cervix cancer using [KO Validated] p16INK4a/CDKN2A Rabbit mAb (NBP3-15420) at dilution of 1:100 (40x lens).Perform microwave antigen retrieval with 10 mM PBS buffer pH 7.2 before commencing with IHC staining protocol.](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-0D0C8-Immunohistochemistry-Paraffin-NBP3-15420-img0002.jpg)
![<b>Genetic Strategies Validation. </b>Knockout Validated: p16INK4a/CDKN2A Antibody (0D0C8) [NBP3-15420] - Analysis of extracts from normal (control) and p16INK4a/CDKN2A knockout (KO) 293T cells, using p16INK4a/CDKN2A Rabbit mAb (NBP3-15420) at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit. Exposure time: 3min.](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-0D0C8-Knockout-Validated-NBP3-15420-img0001.jpg)
![Immunohistochemistry-Paraffin: p14ARF/CDKN2A Antibody (4C6/4) [NBP3-07234] - Formalin-fixed, paraffin-embedded human Brain stained with p14ARF/CDKN2A Mouse Monoclonal Antibody (4C6/4).](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-4C6-4-Immunohistochemistry-Paraffin-NBP3-07234-img0001.jpg "Immunohistochemistry-Paraffin: p14ARF/CDKN2A Antibody (4C6/4) [NBP3-07234] - Formalin-fixed, paraffin-embedded human Brain stained with p14ARF/CDKN2A Mouse Monoclonal Antibody (4C6/4).")
![Immunohistochemistry-Paraffin: p14ARF/CDKN2A Antibody (4C6/4) [NBP3-07234] - Formalin-fixed, paraffin-embedded rat Brain stained with p14ARF/CDKN2A Mouse Monoclonal Antibody (4C6/4).](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-4C6-4-Immunohistochemistry-Paraffin-NBP3-07234-img0002.jpg)
![Western Blot: p14ARF Antibody [NB110-59085] - Detection of CDKN2A in HeLa whole cell extract.](http://images.novusbio.com/fullsize/p14ARF-Antibody-Western-Blot-NB110-59085-img0003.jpg "Western Blot: p14ARF Antibody [NB110-59085] - Detection of CDKN2A in HeLa whole cell extract.")
![Western Blot: p14ARF/CDKN2A Antibody [NB200-159] - Western blot detection of p14ARF uding NB200-159. Samples: WCE (25 ug) from BT549, positive control and U205 negative control and transfected IMR90 cells.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-159-img0002.jpg "Western Blot: p14ARF/CDKN2A Antibody [NB200-159] - Western blot detection of p14ARF uding NB200-159. Samples: WCE (25 ug) from BT549, positive control and U205 negative control and transfected IMR90 cells.")
![Immunohistochemistry: p14ARF/CDKN2A Antibody [NB200-159] - Sample: FFPE section of human prostate carcinoma. Antibody: Affinity purified rabbit anti- p14ARF/p16INK4a used at a dilution of 1:1,000 (1ug/ml). Detection: DAB](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunohistochemistry-NB200-159-img0003.jpg)
![Immunohistochemistry-Paraffin: p14ARF/CDKN2A Antibody [NB200-159] - FFPE section of human prostate adenocarcinoma. Affinity purified rabbit anti-p14ARF used at a dilution of 1:250.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunohistochemistry-Paraffin-NB200-159-img0001.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-158] - Samples : Whole cell lysate (25 ug) from BT549 (positive control), U2OS (negative control) and p14ARF/p16INK4a transfected IMR90 cells. Antibody : Affinity purified rabbit anti-p14ARF/p16INK4a used at 1 ug/ml. Detection : Chemiluminescence.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-158-img0002.jpg "Western Blot: p14ARF/CDKN2A Antibody [NB200-158] - Samples : Whole cell lysate (25 ug) from BT549 (positive control), U2OS (negative control) and p14ARF/p16INK4a transfected IMR90 cells. Antibody : Affinity purified rabbit anti-p14ARF/p16INK4a used at 1 ug/ml. Detection : Chemiluminescence.")
![Immunohistochemistry: p14ARF/CDKN2A Antibody [NB200-158] - Sample: FFPE section of human prostate carcinoma. Antibody: Affinity purified rabbit anti- p14ARF/p16INK4a used at a dilution of 1:1,000 (1ug/ml). Detection: DAB](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunohistochemistry-NB200-158-img0003.jpg)
![SDS-Page: Human p16 TAT Protein [NBP2-35200]](http://images.novusbio.com/fullsize/Human-p16-TAT-Protein-SDS-Page-NBP2-35200-img0001.jpg "SDS-Page: Human p16 TAT Protein [NBP2-35200]")